Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durable benefi...

詳細記述

保存先:
書誌詳細
出版年:J Transl Med
主要な著者: Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6080500/
https://ncbi.nlm.nih.gov/pubmed/30081936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1595-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料